Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41408-021-00408-4
Title: Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
Authors: Murray, David L
Puig, Noemi
Kristinsson, Sigurdur
Usmani, Saad Z
Dispenzieri, Angela
Bianchi, Giada
Kumar, Shaji
Chng, Wee Joo 
Hajek, Roman
Paiva, Bruno
Waage, Anders
Rajkumar, S Vincent
Durie, Brian
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
Hematology
MINIMAL RESIDUAL DISEASE
FREE LIGHT-CHAINS
VARIABLE REGIONS
FLOW-CYTOMETRY
SERUM
PEPTIDES
IDENTIFICATION
SENSITIVITY
CRITERIA
KAPPA
Issue Date: 1-Feb-2021
Publisher: SPRINGERNATURE
Citation: Murray, David L, Puig, Noemi, Kristinsson, Sigurdur, Usmani, Saad Z, Dispenzieri, Angela, Bianchi, Giada, Kumar, Shaji, Chng, Wee Joo, Hajek, Roman, Paiva, Bruno, Waage, Anders, Rajkumar, S Vincent, Durie, Brian (2021-02-01). Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. BLOOD CANCER JOURNAL 11 (2). ScholarBank@NUS Repository. https://doi.org/10.1038/s41408-021-00408-4
Abstract: Plasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce. Traditionally, serum protein electrophoresis methods have been utilized to detect and isotype M-proteins. Increasing demands to detect low-level disease and new therapeutic monoclonal immunoglobulin treatments have stretched the electrophoretic methods to their analytical limits. Newer techniques based on mass spectrometry (MS) are emerging which have improved clinical and analytical performance. MS is gaining traction into clinical laboratories, and has replaced immunofixation electrophoresis (IFE) in routine practice at one institution. The International Myeloma Working Group (IMWG) Mass Spectrometry Committee reviewed the literature in order to summarize current data and to make recommendations regarding the role of mass spectrometric methods in diagnosing and monitoring patients with myeloma and related disorders. Current literature demonstrates that immune-enrichment of immunoglobulins coupled to intact light chain MALDI-TOF MS has clinical characteristics equivalent in performance to IFE with added benefits of detecting additional risk factors for PCDs, differentiating M-protein from therapeutic antibodies, and is a suitable replacement for IFE for diagnosing and monitoring multiple myeloma and related PCDs. In this paper we discuss the IMWG recommendations for the use of MS in PCDs.
Source Title: BLOOD CANCER JOURNAL
URI: https://scholarbank.nus.edu.sg/handle/10635/228998
ISSN: 20445385
DOI: 10.1038/s41408-021-00408-4
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders an International Myelo.pdfPublished version467.5 kBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

26
checked on Oct 1, 2022

Page view(s)

24
checked on Sep 29, 2022

Download(s)

3
checked on Sep 29, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.